Xiaoping Wu
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Pathology and Forensic Medicine top 10%
- Cancer Mechanisms and Therapy
Papers in
- Epidemiology 12
- Liver Disease Diagnosis and Treatment 7
- Adipokines, Inflammation, and Metabolic Diseases 2
- Surgery 7
- Diagnosis and treatment of tuberculosis 3
- Co-authors
- Ming Shi (1 shared paper)Li Xu (1 shared paper)Zhongguo Zhou (1 shared paper)QiJiong Li (1 shared paper)Ruhai Zou (1 shared paper)Guosheng Tan (1 shared paper)Yong Le (1 shared paper)Ying Guo (1 shared paper)
In The Last Decade
Xiaoping Wu
27 papers receiving 730 citations
Hit Papers
Peers
Comparison fields: 5 of 85
- Hepatology 345
- Pathology and Forensic Medicine 183
- Epidemiology 217
- Surgery 226
- Infectious Diseases 81
Countries citing papers authored by Xiaoping Wu
This map shows the geographic impact of Xiaoping Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoping Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoping Wu more than expected).
Fields of papers citing papers by Xiaoping Wu
This network shows the impact of papers produced by Xiaoping Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoping Wu. The network helps show where Xiaoping Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaoping Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion Hit paper breakdown → | 2019 | 372 |
| 2 | 2017 | 83 | |
| 3 | 2019 | 45 | |
| 4 | 2010 | 42 | |
| 5 | 2022 | 32 | |
| 6 | 2013 | 25 | |
| 7 | 2014 | 24 | |
| 8 | 2017 | 19 | |
| 9 | 2021 | 15 | |
| 10 | 2021 | 13 | |
| 11 | 2021 | 12 | |
| 12 | 2022 | 7 | |
| 13 | 2021 | 7 | |
| 14 | 2021 | 7 | |
| 15 | 2022 | 5 | |
| 16 | 2021 | 5 | |
| 17 | 2020 | 4 | |
| 18 | 2016 | 4 | |
| 19 | 2019 | 3 | |
| 20 | 2024 | 3 |
About Xiaoping Wu
Xiaoping Wu is a scholar working on Epidemiology, Surgery, Infectious Diseases, Hepatology and Molecular Biology, having authored 29 papers that have together received 735 indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (7 papers), COVID-19 Clinical Research Studies (4 papers), Liver Disease and Transplantation (4 papers), Drug-Induced Hepatotoxicity and Protection (3 papers), Diagnosis and treatment of tuberculosis (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Adipokines, Inflammation, and Metabolic Diseases (2 papers) and Alcohol Consumption and Health Effects (2 papers). The work is most often cited by research in Hepatology (345 citations), Pathology and Forensic Medicine (183 citations), Epidemiology (217 citations), Surgery (226 citations) and Infectious Diseases (81 citations). Xiaoping Wu has collaborated with scholars based in China, Hong Kong and Germany. Frequent co-authors include Ming Shi, Li Xu, Zhongguo Zhou, QiJiong Li, Ruhai Zou, Guosheng Tan, Yong Le, Ying Guo, JingXian Shen and Ming Zhao. Their work appears in journals such as Lipids in Health and Disease, Information Sciences, Scientific Reports, Medicine and Advances in Clinical and Experimental Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.